BeiGene's BTK inhibitor gets U.S. breakthrough designation

BeiGene Ltd. (NASDAQ:BGNE; HKSE:6160) said FDA granted breakthrough therapy designation to zanubrutinib (BGB-3111) to treat second-line mantle cell lymphoma (MCL). BeiGene President and General Manager of China Xiaobing Wu told BioCentury zanubrutinib is the first cancer therapy from mainland China to receive

Read the full 424 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE